MOLBREEVI (molgramostim inhalation solution) — PDUFA
Nov 22
The FDA determined that the Company's responses to recent information requests by the Agency during their review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.Source filing